Trial reportBMC medicine2026
Spectral focused imaging enables enhanced colorectal adenoma detection: a multicenter, parallel randomized controlled trial.
Trial report in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06603948 (Colorectal Adenoma Detection Using Spectral Focused Imaging Versus White Light Imaging), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Colorectal Adenoma Detection Using Spectral Focused Imaging Versus White Light Imaging: a Parallel Randomized Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe adenoma detection rate (ADR) indicates colonoscopy quality. White light imaging (WLI) often fails to identify small/flat adenomas. Spectral focused imaging (SFI) utilizes multiple narrow-band wavelengths to enhance mucosal visualization. Here, the diagnostic performance of SFI and high-definition WLI were first compared, focusing on ADR.
methodsThis prospective, parallel-arm, randomized controlled trial was undertaken in eight endoscopy centers. Participants (aged 45-85 years) were randomly allocated (1:1) to SFI and high-definition WLI groups. The primary endpoint was ADR, while secondary endpoints included the polyp detection rate (PDR), advanced ADR (aADR), and the average adenoma number per colonoscopy. Exploratory subgroup analyses compared detection of lesions differing in size, morphology, and anatomical location.
resultsSix hundred and ninety-eight patients were allocated to groups (SFI: n = 350; WLI: n = 348). The ADR was markedly greater in the SFI group (38.29% vs. 30.46%; P = 0.030), as were secondary measures: PDR (56.29% vs. 47.99%; P = 0.028), aADR (6.57% vs. 3.16%; P = 0.036), and adenoma number per colonoscopy (0.74 vs. 0.51; P = 0.021). Exploratory subgroup analysis indicated that SFI was superior in detecting right-sided adenomas (17.71% vs. 11.78%; P = 0.027), diminutive lesions ≤ 5 mm (28.86% vs. 19.54%; P = 0.004), and flat adenomas (22.86% vs. 16.67%; P = 0.040).
conclusionsSFI was significantly more effective in adenoma detection relative to high-definition WLI, particularly for right-colon and small/flat lesions. These findings support the use of SFI in routine endoscopy to enhance colonoscopy quality and detection of colorectal adenomas.
trial registrationClinicalTrials, NCT06603948.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.